Company code: 603122 company abbreviation: Hefu China Hefu (China) Medical Technology Co., Ltd
Summary of annual report 2021
Section I important tips
1 the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should go to www.sse.com com. cn. The website carefully reads the full text of the annual report. 2. The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 3. All directors of the company attend the board meeting. 4 KPMG Huazhen Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 5. The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
On March 21, 2022, the board of directors proposed that the company distribute cash dividends to ordinary shareholders. Based on the total share capital registered on the date of equity distribution, it plans to distribute cash dividends of RMB 0.18 per share (including tax) to all shareholders. It is expected to distribute a total of RMB 7164947394 (including tax), and the remaining undistributed profits will be carried forward to future annual distribution. The company does not convert the capital reserve into share capital and does not give bonus shares. This proposal has yet to be approved by the general meeting of shareholders.
Section II basic information of the company
1 company profile
Company stock profile
Stock type stock exchange stock abbreviation stock abbreviation before stock code change
A-share Shanghai Stock Exchange Hefu China 603122 is not applicable
Contact person and contact information secretary of the board of directors securities affairs representative
Name: CHEN Ye-
Office address: Guangqi building, 456 Hongcao Road, Xuhui District, Shanghai-
Tel: 021 Thinker Agricultural Machinery Co.Ltd(603789) 99-
E-mail [email protected]. –
2. Introduction to the company’s main business in the reporting period
(1) Development trend of in vitro diagnosis industry in China
China’s in vitro diagnosis industry is in a stage of rapid development. In the future, China’s in vitro diagnosis industry will develop in three directions: import substitution of high-end immunity, upgrading of molecular diagnosis technology and convenience of POCT:
At present, high-end chemiluminescence has become the mainstream immunodiagnostic method in China. The market scale has reached more than 70% of the total immunodiagnostic market, and is basically monopolized by Roche, Abbott, Beckman and other foreign giants. In recent years, with the breakthrough of Chinese enterprises in chemiluminescence technology, they have not only realized localization in the medium and low-end immunodiagnosis, but also began to realize a small part of import substitution in the high-end immunodiagnosis field monopolized by overseas giants. In the future, with the technological breakthrough of Chinese advantageous enterprises, the cost performance advantage of localization and the help of industrial policies, it is expected to gradually realize the import substitution in the field of high-end immunodiagnosis.
Molecular diagnosis technology has developed for a short time, and the technical level gap between Chinese enterprises and their overseas counterparts is relatively small. Molecular diagnosis is mainly divided into PCR, gene chip, gene sequencing and other technologies. In the long run, gene sequencing technology has a broader development space, but its cost is high. At present, PCR technology is still the mainstream of molecular diagnosis. Benefiting from the development trend of precision medicine and the continuous upgrading of technical means of molecular diagnosis itself, molecular diagnosis will continue to grow rapidly for a considerable period of time in the future.
China is actively promoting graded diagnosis and treatment, so that the diagnosis and treatment dominated by central hospitals will be transferred to secondary and community hospitals. The resulting demand for rapid detection will make POCT have broad prospects for development. In terms of grass-roots hospitals, benefiting from the impact of the trend of graded diagnosis and treatment, more patients will choose to receive preliminary examination in grass-roots hospitals. As common diseases, chronic diseases and frequently occurring diseases are the mainstream of treatment in grass-roots hospitals, and POCT’s advantages in timeliness and flexibility can meet the needs of basic diagnosis and testing, and make up for the lack of diagnostic resources in grass-roots hospitals, grass-roots hospitals will be the market for the rapid development of POCT in the future.
(2) Development trend of in vitro diagnostic product circulation and service industry
With the intensification of market competition, the market will gradually concentrate on intensive comprehensive service providers that can provide a package of value-added services, and the industry concentration will gradually increase. Industry competition will be reflected in the comprehensive competition in many fields, such as product variety, service network and business scale, warehouse management and logistics distribution capacity, technical support services, customer response ability and so on.
A. Service network and business scale expansion
After the business scale of intensive integrated service providers reaches a certain degree, they can obtain competitive advantages in the comprehensiveness of market network coverage and the completeness of product types. While realizing the scale effect, they can obtain higher procurement cost advantages, and seize the market by providing customers with products and overall integrated services
The wider the service network of service providers covers, the easier it is to be recognized by product manufacturers and customers. It is also conducive to providing customers with stable and fast localized services through the service network distributed all over the country, providing customers with all-round product supply, logistics distribution and technical services nationwide, and providing necessary guarantee for more high-quality customers.
B. Improvement of comprehensive service capacity
With the increasingly clear division of labor between in vitro diagnostic product manufacturers and service providers, end users of in vitro diagnostic products have higher and higher requirements for the comprehensive service ability of service providers. They not only require service providers to provide daily services such as warehousing management, logistics distribution, maintenance and timely response, but also hope that service providers can provide more value-added services at multiple levels such as hospital management.
C. The hospital has higher requirements for fine management
According to the opinions of the general office of the State Council on promoting the high-quality development of public hospitals issued by the general office of the State Council in June 2021, the test belongs to one of strengthening the construction of clinical specialties and requires to improve the new efficiency of high-quality development of public hospitals, which are as follows: 1) improve the operation and management system; 2) Strengthening comprehensive budget management; 3) Improve the internal control system; 4) Improve the performance evaluation mechanism; 5) Improve the training and evaluation system of medical personnel; 6) Strengthen the supporting role of informatization.
According to the requirements of the National Health Care Commission for deepening the reform of medical service quality and specialization in August, 2021, the National Health Care Commission issued the joint plan for deepening the reform of public health care institutions and strengthening the coordination of medical service prices, according to the requirements of the National Health Care Commission.
Therefore, terminal hospitals have urgent needs for the transformation from extensive management to fine management.
During the reporting period, the company was mainly engaged in the following businesses:
(1) Intensive business of in vitro diagnostic products
Guided by the actual personalized needs of end customers, the company effectively integrates the resources of upstream suppliers, constructs a perfect integrated service system, carries out intensive sales business and provides value-added services for customers such as medical institutions. The intensive business of in vitro diagnostic products of the company signs medium and long-term business contracts with medical institutions. As a centralized supplier, the company provides overall supply chain management services for in vitro diagnostic products for medical institutions, negotiates and purchases with suppliers according to product types and brand requirements, and uniformly purchases, distributes and manages the overall reagent and consumables needs of medical institutions; At the same time, the company dispatched special personnel to assist medical institutions in inventory management, purchase volume estimation, department professional training, information construction and other work, so as to further reduce the proportion of consumption for hospitals.
(2) Circulation of medical products
In the circulation business of medical products, the company is guided by the channel network led by the upstream original factory and its major agents, and actively gives full play to the channel advantages.
Specifically, the circulation business of the company’s medical products mainly includes the sales of equipment in the field of radiation and swelling and the sales of maintenance, immune diagnosis, biochemical diagnosis and other equipment. At the same time, it can also expand the scope of products and services according to the actual needs of upstream and downstream
(3) Other value-added services
China’s Chinese mainland Chinese mainland Medical China is also a bridge to link up high-quality resources in mainland China. It also helps Taiwan medical experts in China to conduct professional guidance and co construction of departments, so as to facilitate the sharing of resources between Mainland and Taiwan medical institutions and achieve win-win cooperation between Chinese mainland and mainland medical institutions. In addition, the company provides support services for overseas original factories to apply for medical device registration certificate in China, and charges service fees. 3 main accounting data and financial indicators of the company 3.1 main accounting data and financial indicators in recent three years
Unit: yuan currency: RMB
20212020 compared with 2019 of the previous year
Increase or decrease (%)
Total assets 112054777527109944953522 1.9211 Shenzhen Bestek Technology Co.Ltd(300822) 8456
Attributable to listed companies
The net capital of the company’s shareholders is 7958326067171702420317 10.9978940562318
Operating income 119106016911108902352228 9.37104697514462
Attributable to listed companies
The net profit of shareholders of the company is 80230457527255385568 10.586714485062, which belongs to the listed company
The net profit of the company’s shareholders deducting 75771125787344283198 3.176651458702 non recurring profits and losses is generated from operating activities
Net cash flow of 7011510707415470447 -90.54 -3789102045
The weighted average net asset was 10.61 9.06, an increase of 1.55% and 11.39 yield (%) points
Basic earnings per share 0.27 0.24 12.50 0.26 (yuan / share)
Diluted earnings per share 0.27 0.24 12.50 0.26 (yuan / share)
3.2 main accounting data by quarter in the reporting period
Unit: RMB
First quarter second quarter third quarter fourth quarter
(January March) (April June) (July September) (October December)
Operating income 25735570200341859508772998852372529195972109
The net profit attributable to the shareholders of the listed company 1411988502211119655818569901282642870564 belongs to the shareholders of the listed company
Net profit after deducting non recurring profit and loss 1284795298234610592814212611832524950169
Cash generated from operating activities – 129587750268192070522 – 15455722167013427790 description of the difference between quarterly data of net flow and data in the disclosed periodic report □ applicable √ not applicable 4 shareholders 4.1 total number of ordinary shareholders, total number of preferred shareholders with voting rights restored, total number of shareholders holding special voting shares and the top 10 shareholders at the end of the reporting period and the end of the month before the disclosure of the annual report
